Antonios G.A. Kolios

Dr. Antonios G.A. Kolios


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
CSCharlotte Schwab
Charlotte Schwab
AGAnnemarie Gabrysch
Annemarie Gabrysch
POPeter Olbrich
Peter Olbrich
VPVirginia Patiño
Virginia Patiño
KWKlaus Warnatz
Klaus Warnatz
BGBodo Grimbacher
Bodo Grimbacher

1 March 2014 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MKMagdalena Kistowska
Magdalena Kistowska
SGSamuel Gehrke
Samuel Gehrke
DJDragana Jankovic
Dragana Jankovic
KKKatrin Kerl
Katrin Kerl
AFAntonia Fettelschoss-Gabriel
Antonia Fettelschoss-Gabriel
LFLars E. French
Lars E. French

1 May 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
NSNiovi Setta-Kaffetzi
Niovi Setta-Kaffetzi
MSMichael A. Simpson
Michael A. Simpson
ANAlexander A. Navarini
Alexander A. Navarini
VPVarsha M. Patel
Varsha M. Patel
HLHui-Chun Lu
Hui-Chun Lu
FCFrancesca Capon
Francesca Capon

2 November 2021 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
AKAntonios G.A. Kolios
Antonios G.A. Kolios
GTGeorge Tsokos
George Tsokos
DKDavid Klatzmann
David Klatzmann

16 October 2015 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
AKAntonios G.A. Kolios
Antonios G.A. Kolios
JMJ.‐T. Maul
J.‐T. Maul
BMB. Meier
B. Meier
KKK. Kerl
K. Kerl
CTC. Traidl‐Hoffmann
C. Traidl‐Hoffmann
LFL.E. French
L.E. French
Background Pyoderma gangrenosum (PG) is a rare, neutrophilic, ulcerative skin disease that is difficult to treat, especially when unresponsive to steroids. Objectives To determine whether canakinumab is an effective and safe treatment in PG. Methods Five adult patients with clinically and histologically confirmed steroid‐refractory PG were enrolled in this prospective open‐label study. They received canakinumab 150 mg subcutaneously at week 0 with an optional 150 mg at week 2 in case of an inadequate response [Physician's Global Assessment (PGA) ≥ 2], and an optional 150–300 mg at week 8 depending on PGA. The primary clinical end point was clinical improvement (PGA at least −1 from baseline) and/or complete remission (PGA 0 or 1) at week 16. Real‐time quantitative polymerase chain reaction was performed on skin samples to quantify cytokine mRNA levels. Results Interleukin (IL)‐1β and its known target genes IL6, CXCL8 and IL36A were significantly increased in lesional skin of PG. Under canakinumab therapy, four of five patients showed a decrease in target‐lesion size, PGA and Dermatology Life Quality Index (DLQI), and three of five achieved complete remission. The mean diameter of target lesions decreased from 4·32 ± 2·6 cm at visit 1 to 0·78 ± 1·3 cm at visit 7 (P = 0·03). Mean DLQI decreased from 15 ± 5 at visit 1 to 8 ± 4 by visit 7 (P = 0·01). Adverse effects were reported in two patients: fatigue in one and worsening of disease at a nontarget lesion in the other. Conclusions Our data indicate that IL‐1β plays a key pathogenic role in PG and canakinumab may represent a therapeutic option for steroid‐refractory PG.

1 July 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
DIDaniela Impellizzieri
Daniela Impellizzieri
FRFrederike Ridder
Frederike Ridder
MRMiro E. Raeber
Miro E. Raeber
CECecilie Egholm
Cecilie Egholm
JWJanine Woytschak
Janine Woytschak
OBOnur Boyman
Onur Boyman